📢Market Bulletin
WHO Guidelines & GMP Standards (4)
Permanent Category Link →WHO Guidelines on Climatic Zone IVb Stability Testing for Active Pharmaceutical Ingredients & FPPs
Technical compliance notice for exporters shipping Active Pharmaceutical Ingredients (APIs) and Finished Pharmaceutical Products (FPPs) to tropical and hot/humid regions (ASEAN, MENA, South Asia, Sub-Saharan Africa). Long-term stability studies must strictly satisfy Climatic Zone IVb parameters (30°C ± 2°C / 75% RH ± 5% RH). Photostability & Excursions: ICH Q1B photostability verification and USP <1079> mean kinetic temperature (MKT) excursion profiles required for sea-freight shipments. Moisture Barrier Packaging: High-barrier Alu-Alu cold-form foil or HDPE bottles with desiccant canisters validated per USP <671> moisture vapor transmission rates. Official Source & Verification Reference Issuing Authority: World Health Organization (WHO) Expert Committee • Reference: WHO-TRS-1010-Z4B Verify Official Source Document ↗
Comprehensive Update: WHO Pharmaceutical Quality Assurance, GMP Compliance, and Global Trade Regulations (2026)
Comprehensive Update: WHO Pharmaceutical Quality Assurance, GMP Compliance, and Global Trade Regulations (2026) Introduction and Executive Summary: In the fast-evolving landscape of global healthcare commerce, the World Health Organization (WHO) continues to reinforce its regulatory frameworks to govern active pharmaceutical ingredients (APIs), finished medicinal formulations, and surgical medical devices. As international B2B trade automation expands, maintaining stringent quality standards, ensuring supply chain transparency, and eliminating substandard or falsified medical products remain top priorities for regulatory authorities, global buyers, and pharmaceutical manufacturers worldwide. 1. Evolving Good Manufacturing Practices (GMP) and Quality Control: The updated 2026 guidelines place heavy emphasis on modernizing Good Manufacturing Practices (GMP) across all production facilities. Key focus areas include: • Advanced validation of manufacturing equipment and digital computerized systems used in pharmaceutical production. • Rigorous testing protocols for active pharmaceutical ingredients (APIs) to prevent cross-contamination and ensure batch-to-batch consistency. • Integration of automated electronic data recording to support transparent compliance auditing and swift cross-border regulatory approvals. 2. Eradication of Substandard and Falsified (SF) Medical Products: Combatting counterfeit and substandard medicines is critical for protecting public health and maintaining trust in global B2B platforms. The WHO framework outlines: • Enhanced utilization of the Global Surveillance and Monitoring System (GSMS) for rapid reporting and tracking of illicit products. • Implementation of secure serialisation, track-and-trace technologies, and cryptographic verification codes on packaging to protect supply chains. • Stricter penalties and coordinated international actions against unauthorized manufacturing units and rogue distributors. 3. Streamlining International Supply Chains and Essential Medicines: To support uninterrupted access to life-saving therapeutics and medical hardware, the updated policies focus on: • Periodic revision and expansion of the WHO Model List of Essential Medicines (EML) to address emerging global health challenges. • Harmonization of inspection procedures among National Regulatory Authorities (NRAs) to reduce bureaucratic delays in international shipping and export-import documentation. • Encouraging diversified sourcing strategies to prevent market monopolies and mitigate supply chain vulnerabilities during global crises. Conclusion and Future Outlook: Compliance with these updated WHO guidelines is no longer optional for serious stakeholders in the B2B pharmaceutical sector. Platforms and enterprises that adopt these digital compliance measures, maintain verifiable documentation, and align with international standards will lead the future of secure medical trade. Official References and Documentation: For further reading, complete regulatory text, and official documentation downloads, please visit the official World Health Organization portal: Source: World Health Organization (WHO) – Regulation and Prequalification Department Official Link: https://www.who.int/teams/regulation-prequalification
Sterile Medicinal Products GMP: Contamination Control Strategy (CCS) & Aseptic Isolator Standards
Regulatory inspection benchmark for sterile parenteral facilities ( HS Code 3004.90 ) enforcing holistic Contamination Control Strategies (CCS) across Grade A–D cleanroom zones. Facilities utilizing Restricted Access Barrier Systems (RABS) or closed isolators must validate automated Vaporized Hydrogen Peroxide (VHP) bio-decontamination cycles. Environmental Monitoring: Continuous non-viable particulate counting (≥0.5 μm and ≥5.0 μm) in Grade A filling zones; zero CFU tolerance on settle plates and contact plates during aseptic processing. Container Closure Integrity: 100% deterministic Container Closure Integrity Testing (CCIT) such as High-Voltage Leak Detection (HVLD) or vacuum decay for fusion-sealed ampoules and vials. Official Source & Verification Reference Issuing Authority: World Health Organization (WHO) Prequalification & GMP Unit • Reference: WHO-GMP-STERILE-2026 Verify Official Source Document ↗
WHO Technical Report Series Update: Water for Injection (WFI) Membrane Generation & TOC Control
Updated Good Manufacturing Practice (GMP) technical guidance addressing non-distillation Water for Injection (WFI) production via dual-pass Reverse Osmosis (RO) coupled with Electrodeionization (EDI) and ultrafiltration. Harmonized with Ph. Eur. Monograph 0169 and USP <1231> water system specifications. Critical Limits: Total Organic Carbon (TOC) ≤ 500 ppb; bacterial endotoxins < 0.25 EU/mL; total viable aerobic count ≤ 10 CFU/100 mL; temperature-compensated conductivity ≤ 1.1 μS/cm at 20°C. Validation Mandate: Manufacturers must maintain continuous online TOC/conductivity monitoring and 12-month seasonal biofilm trend evaluations. Official Source & Verification Reference Issuing Authority: World Health Organization (WHO) • Reference: WHO-TRS-1044-WFI-2026 Verify Official Source Document ↗
